AAA_Algernon SWL - pending

Source: Streetwise Reports (2/9/22)

Canadian Hedge Fund CIO Talks Top 2022 Prospects
Source: Streetwise Reports (02/09/2022)

AlphaNorth Asset Management was recently recognized as the Number One equity hedge fund in Canada at the 2021 Alternative IQ Canadian Hedge Fund Awards due to its 5-year average investment return of 40.35%. Streetwise Reports sat down with the firm's co-Founder Steven Palmer to discuss some of the firm's recent investments and emerging opportunities for 2022.

Todos COVID-19 Drug Shows Superiority to Remdesivir, Takes Dying Off the Table
Source: Vision and Value (02/08/2022)

In a phase 2 clinical study, Todos Medical's oral antiviral Tollovir showed a 100% reduction in mortality from COVID-19.

Investors: Will a Psychedelic Drug Take This Pharma Stock to the Next Level?
Source: Streetwise Reports (02/07/2022)

Algernon Pharmaceuticals plans to be the world's first company to test the psychedelic drug DMT in stroke patients, and it's close to achieving its goal.

Drug Re-Purposing Co. Pursues Novel Stroke Therapies
Source: Streetwise Reports (02/03/2022)

Drug re-purposing co. Algernon Pharmaceuticals Inc. is actively reinventing itself. The firm's leading therapeutic candidate NP-120 (Ifenprodil) is currently being evaluated in a Phase 2 trial for IPF and chronic cough, and the company is now moving forward with a revolutionary new use for DMT to treat ischemic stroke.

Biopharma Co. to Resubmit BLA to FDA for Type 1 Diabetes
Source: Streetwise Reports (01/31/2022)

Shares of Provention Bio Inc. traded 29% higher after the company reported that following its Type B meeting and conversations with the U.S. FDA, it is now planning to resubmit a Biologics License Application for delay of clinical type 1 diabetes in at-risk individuals.